Capmatinib in
Publication/Presentation Date
9-3-2020
Abstract
BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC),
METHODS: We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with
RESULTS: A total of 364 patients were assigned to the cohorts. Among patients with NSCLC with a
CONCLUSIONS: Capmatinib showed substantial antitumor activity in patients with advanced NSCLC with a
Volume
383
Issue
10
First Page
944
Last Page
957
ISSN
1533-4406
Published In/Presented At
Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., Smit, E. F., Souquet, P. J., Vansteenkiste, J., Hochmair, M., Felip, E., Nishio, M., Thomas, M., Ohashi, K., Toyozawa, R., Overbeck, T. R., … GEOMETRY mono-1 Investigators (2020). Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. The New England journal of medicine, 383(10), 944–957. https://doi.org/10.1056/NEJMoa2002787
Disciplines
Medicine and Health Sciences
PubMedID
32877583
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article